Aurigene Oncology Ltd. and Olema Pharmaceuticals Inc. have jointly patented acylsulfonamide histone acetyltransferase KAT6A (monocytic leukemia zinc finger protein; MOZ; MYST-3) inhibitors reported to ...
For example, some lysine acetyltransferases such as KAT6A were considered undruggable for many years. The Cooperative Research Centre for Cancer Therapeutics bridged the risk gap from genetic ...